PMID- 29966739
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20200106
IS  - 1873-474X (Electronic)
IS  - 0736-5748 (Linking)
VI  - 69
DP  - 2018 Oct
TI  - Hesperetin and it nanocrystals ameliorate social behavior deficits and 
      oxido-inflammatory stress in rat model of autism.
PG  - 80-87
LID - S0736-5748(17)30327-1 [pii]
LID - 10.1016/j.ijdevneu.2018.06.009 [doi]
AB  - Prenatal exposure to valproic acid (VPA) induces behavioral disorders and 
      enhancement of oxido-inflammatory stress in Autism Spectrum Disorders (ASDs). The 
      aim of this study was to investigate the comparative effects of hesperetin (Hst) 
      and nano-hesperetin on social behavior deficits and oxido-inflammatory indexes in 
      prenatally valproic acid-exposed rat offspring. Pregnant Wistar rats on embryonic 
      day 0 (E0) were segregated into six groups; Group-1 served as vehicle, received 
      distillated water orally (PO) from E1 until the end of lactation and saline 
      intraperitoneally (i.p) on E12.5. Group-2 received sodium valproate (500 mg/kg in 
      0.9% saline, i.p) on E12.5 was considered as VPA-exposed group, Group-3 to 6 were 
      VPA-exposed which received hesperetin and nano-hesperetin (10 and 20 mg/kg/day, 
      PO) from E0 until the end of lactation respectively. Social interaction and open 
      field tests were conducted on postnatal day 28 (PND 28) and PND 30, cerebral 
      antioxidant enzymes activity and biochemical indexes, the level of inflammatory 
      factors in plasma and histopathology of cerebellum were estimated on PND 28 and 
      PND 30. Prenatal valproic acid-exposed rat exhibited poor sociability and high 
      level of anxiety-like behaviors (P <  0.05). In addition, increased level of 
      oxidative stress and inflammation were found by determining different 
      oxido-inflammatory markers. Hesperetin and nano-hesperetin treatment improved the 
      behavioral disorder and reduced the oxidative stress in brain and significantly 
      (p <  0.05) plasma's inflammation indexes. In conclusion, it can be state that 
      nano-hesperetin exerts neuroprotective action in comparison with hesperetin and 
      could be efficacious for treatment of VPA animal model of autism during pregnancy 
      and lactation.
CI  - Copyright (c) 2018 ISDN. Published by Elsevier Ltd. All rights reserved.
FAU - Khalaj, Rashin
AU  - Khalaj R
AD  - Department of Biology, Faculty of Basic Sciences, University of Mazandaran, 
      Babolsar, Iran.
FAU - Hajizadeh Moghaddam, Akbar
AU  - Hajizadeh Moghaddam A
AD  - Department of Biology, Faculty of Basic Sciences, University of Mazandaran, 
      Babolsar, Iran. Electronic address: a.hajizadeh@umz.ac.ir.
FAU - Zare, Mahboobeh
AU  - Zare M
AD  - Faculty of Herbs, Amol University of Special Modern Technologies, Amol, Iran.
LA  - eng
PT  - Journal Article
DEP - 20180630
PL  - United States
TA  - Int J Dev Neurosci
JT  - International journal of developmental neuroscience : the official journal of the 
      International Society for Developmental Neuroscience
JID - 8401784
RN  - 0 (Anticonvulsants)
RN  - 0 (Antioxidants)
RN  - 0 (Cytokines)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - E750O06Y6O (Hesperidin)
RN  - Q9Q3D557F1 (hesperetin)
SB  - IM
MH  - Animals
MH  - Anticonvulsants
MH  - Antioxidants/metabolism
MH  - Autistic Disorder/chemically induced/*drug therapy/*psychology
MH  - Birth Weight
MH  - Brain Chemistry/drug effects
MH  - Cytokines/metabolism
MH  - Female
MH  - Hesperidin/chemistry/*pharmacology/therapeutic use
MH  - Inflammation/chemically induced/*drug therapy/*psychology
MH  - Interpersonal Relations
MH  - Motor Activity/drug effects
MH  - *Nanoparticles
MH  - Oxidative Stress/*drug effects
MH  - Pregnancy
MH  - Prenatal Exposure Delayed Effects
MH  - Rats
MH  - Rats, Wistar
MH  - *Social Behavior
MH  - Valproic Acid
OTO - NOTNLM
OT  - Autism
OT  - Inflammation
OT  - Nano-hesperetin
OT  - Oxidative stress
OT  - Valproic acid
EDAT- 2018/07/04 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/07/04 06:00
PHST- 2018/01/29 00:00 [received]
PHST- 2018/04/28 00:00 [revised]
PHST- 2018/06/24 00:00 [accepted]
PHST- 2018/07/04 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/07/04 06:00 [entrez]
AID - S0736-5748(17)30327-1 [pii]
AID - 10.1016/j.ijdevneu.2018.06.009 [doi]
PST - ppublish
SO  - Int J Dev Neurosci. 2018 Oct;69:80-87. doi: 10.1016/j.ijdevneu.2018.06.009. Epub 
      2018 Jun 30.